IL191795A - Use of Bacillus 6pb for the preparation of drugs for the prevention or treatment of gastrointestinal and related disorders @ the @ immune system - Google Patents

Use of Bacillus 6pb for the preparation of drugs for the prevention or treatment of gastrointestinal and related disorders @ the @ immune system

Info

Publication number
IL191795A
IL191795A IL191795A IL19179508A IL191795A IL 191795 A IL191795 A IL 191795A IL 191795 A IL191795 A IL 191795A IL 19179508 A IL19179508 A IL 19179508A IL 191795 A IL191795 A IL 191795A
Authority
IL
Israel
Prior art keywords
treatment
bacillus
prophylaxis
immuno
medicaments
Prior art date
Application number
IL191795A
Other languages
English (en)
Hebrew (he)
Other versions
IL191795A0 (en
Original Assignee
Kemin Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemin Ind Inc filed Critical Kemin Ind Inc
Publication of IL191795A0 publication Critical patent/IL191795A0/en
Publication of IL191795A publication Critical patent/IL191795A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • C12R2001/125—Bacillus subtilis ; Hay bacillus; Grass bacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL191795A 2005-11-29 2008-05-28 Use of Bacillus 6pb for the preparation of drugs for the prevention or treatment of gastrointestinal and related disorders @ the @ immune system IL191795A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74051805P 2005-11-29 2005-11-29
PCT/US2006/045755 WO2007064741A2 (en) 2005-11-29 2006-11-29 The use of bacillus pb6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases

Publications (2)

Publication Number Publication Date
IL191795A0 IL191795A0 (en) 2009-02-11
IL191795A true IL191795A (en) 2013-07-31

Family

ID=38092773

Family Applications (1)

Application Number Title Priority Date Filing Date
IL191795A IL191795A (en) 2005-11-29 2008-05-28 Use of Bacillus 6pb for the preparation of drugs for the prevention or treatment of gastrointestinal and related disorders @ the @ immune system

Country Status (13)

Country Link
US (1) US20080057047A1 (enExample)
EP (1) EP1956914B1 (enExample)
JP (2) JP5280854B2 (enExample)
KR (1) KR101470352B1 (enExample)
CN (1) CN101448398B (enExample)
AU (1) AU2006320613B2 (enExample)
BR (1) BRPI0619364A2 (enExample)
CA (1) CA2631289C (enExample)
IL (1) IL191795A (enExample)
NZ (1) NZ569244A (enExample)
RU (1) RU2412241C2 (enExample)
WO (1) WO2007064741A2 (enExample)
ZA (1) ZA200804646B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2489659T3 (pl) 2004-06-24 2018-06-29 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą atp
PT1993360T (pt) 2005-12-28 2017-05-25 Vertex Pharma Formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-di-hidro-4-oxoquinolina-3-carboxamida
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
PE20120074A1 (es) * 2008-09-17 2012-02-26 Agraquest Inc Composicion que comprende cepa de bacillus subtilis para alimentar animales
MX348019B (es) * 2008-09-24 2017-05-23 Resilux Incorporacion en materiales de organismos termo-resistentes y/o resistentes a la presión.
EP3330255B1 (en) 2009-03-20 2020-12-09 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US20130004475A1 (en) * 2010-03-12 2013-01-03 Misaki Hatanaka Agent for increasing bifidobacteria and reducing the decrease of bifidobacteria in large intestine
DK2547348T3 (da) 2010-03-17 2015-08-24 Bayer Cropscience Lp Fremgangsmåde til anvendelse af en bacillus subtilis-stamme til profylakse og behandling af mave-tarm-tilstande
WO2012009712A2 (en) 2010-07-16 2012-01-19 The Board Of Trustees Of The University Of Arkansas Methods and compositions including spore-forming bacteria for increasing the health of animals
WO2012044984A1 (en) 2010-09-30 2012-04-05 The Board Of Trustees Of The University Of Arkansas Methods of selecting and using therapeutic and prophylactic probiotic cultures to reduce bacterial pathogen loads
CA2834402A1 (en) * 2010-12-29 2012-07-05 Cangene Corporation Clostridium difficile antigens
IL311180A (en) 2012-02-27 2024-04-01 Vertex Pharma Pharmaceutical preparations containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof
US9393275B2 (en) 2012-08-01 2016-07-19 Novozymes A/S Probiotic for amelioration of coccidiosis vaccine reaction
RU2534356C2 (ru) * 2012-10-04 2014-11-27 Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Россельхозакадемии (ГНУ ИЭВСиДВ Россельхозакадемии) Способ контроля качества дезинфекции птицеводческих помещений
FR2999191B1 (fr) * 2012-12-12 2016-02-05 Lesaffre & Cie Souches probiotiques pour le traitement et/ou la prevention de la diarrhee
FR3007655B1 (fr) * 2013-06-28 2016-12-23 Lesaffre & Cie Souche bacillus subtilis pour le traitement et/ou la prevention de maladies inflammatoires chroniques
EP2923710A1 (en) * 2014-03-27 2015-09-30 Universitätsklinikum Heidelberg Bacterial phospholipase inhibitors as modulator of colonic bacterial flora
WO2016011511A1 (en) * 2014-07-25 2016-01-28 The University Of Queensland Bacillus amyloliquefaciens probiotic compositions, methods of production, and methods of use
ES2835731T3 (es) 2014-09-30 2021-06-23 Univ Auburn Uso de pectina o sacáridos relacionados con la pectina para mejorar la eficacia de las cepas de rizobacterias que promueven el crecimiento de las plantas (PGPR) para promover el crecimiento y la salud en las plantas
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
JP6595761B2 (ja) * 2014-12-19 2019-10-23 東亜薬品工業株式会社 バチルスアミロリキファシエンス菌株及び該菌株を含む抗菌組成物
ES2954455T3 (es) 2015-01-23 2023-11-22 Novozymes As Cepas de Bacillus que mejoran la salud y el rendimiento de animales de producción
BR112017015623B1 (pt) 2015-01-23 2022-05-31 Novozymes A/S Ração animal ou aditivo de ração animal ou pré-mistura de ração, método para melhora de um ou mais parâmetros de desempenho de um animal e para alimentação de um animal, e, uso de uma cepa de bacillus
WO2016118850A1 (en) 2015-01-23 2016-07-28 Novozymes A/S Bacillus subtilis subspecies
WO2016194427A1 (ja) * 2015-05-30 2016-12-08 日環科学株式会社 プロバイオティクス、あるいはプレバイオティクス、並びにその製造方法、微生物製剤、健康食品並びに医薬品
US10857190B2 (en) 2015-10-06 2020-12-08 Albert Einstein College Of Medicine Microbial hyperswarmers and uses thereof
JP6759337B2 (ja) * 2015-10-26 2020-09-23 シージェー チェイルジェダン コーポレーション 酵素生産能が優秀である伝統発酵食品由来の新たな菌株及びこれを用いた穀物発酵酵素食品の製造方法
RU2641979C1 (ru) * 2016-10-24 2018-01-23 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московская государственная академия ветеринарной медицины и биотехнологии - МВА имени К.И. Скрябина" (ФГБОУ ВО МГАВМиБ - МВА имени К.И. Скрябина) Способ морфологической оценки влияния различных лекарственных форм железа для энтерального применения на тонкий отдел кишечника у экспериментальных животных
EP3645751A1 (en) * 2017-06-30 2020-05-06 Evonik Operations GmbH Bacillus subtilis
US20190289878A1 (en) * 2018-03-23 2019-09-26 Purina Animal Nutrition Llc Methods of feeding animals feed products containing direct-fed microbials
BR122023002250B1 (pt) * 2018-06-07 2024-01-09 Artugen Therapeutics Ltd Composição para o tratamento de c. difficile
US20220160794A1 (en) * 2019-05-14 2022-05-26 Ormendes Sa Use of bacillus amyloliquefaciens and/or bacillus subtilis for the enhancement of active probiotic compositions or for the activation of inactive probiotic compositions, compositions thus obtained, and related method
WO2020257769A1 (en) * 2019-06-21 2020-12-24 The Board Of Trustees Of The University Of Arkansas Bacillus isolate compositions and methods of using and producing the same
GB201911925D0 (en) * 2019-08-20 2019-10-02 Sporegen Ltd Formulations for prevention or reduction of c. difficile infections
WO2021116983A1 (en) * 2019-12-11 2021-06-17 Artugen Therapeutics, Ltd. Edible products comprising bacterial strains and methods of use
US20210283199A1 (en) * 2020-03-13 2021-09-16 Kemin Industries, Inc. Method for controlling clostridium infection in animals
GB202013874D0 (en) * 2020-09-03 2020-10-21 Sporegen Ltd Treatment and prevention of viral infections
US12317906B2 (en) 2020-12-09 2025-06-03 Purina Animal Nutrition Llc Feed compositions and methods for inhibiting focal ulcerative dermatitis
CN113151069B (zh) * 2021-04-01 2022-07-26 安杰利(重庆)生物科技有限公司 一种枯草芽孢杆菌及其在制备抗菌肽、饲料中的应用
KR102546973B1 (ko) * 2021-10-20 2023-06-26 주식회사 리빙진 바실러스 밸레젠시스 Kh2-2 균주를 포함하는 면역증강용 조성물
WO2023220279A1 (en) * 2022-05-12 2023-11-16 Can Technologies, Inc. Compositions and methods for the treatment and prevention of campylobacter infection
CN115725461B (zh) * 2022-11-03 2024-03-19 东北农业大学 一株具有抗幽门螺杆菌作用的解淀粉芽孢杆菌及其应用
FR3158224A1 (fr) * 2024-01-12 2025-07-18 Lesaffre Et Compagnie Effet bénéfique d’une bactérie probiotique Bacillus subtilis dans la lutte contre les infections

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968493A (en) * 1986-06-30 1990-11-06 American Cyanamid Company Method for controlling chronic respiratory disease, fowl cholera and necrotic enteritis in avian species
US5352586A (en) * 1987-05-01 1994-10-04 Biogaia Ab Method of determining the presence of an antibiotic produced by Lactobacillus reuteri
ZA926834B (en) * 1991-09-09 1993-03-15 American Cyanamid Co Antibiotic LL-E19020 Gamma.
TW455591B (en) * 1993-06-08 2001-09-21 Hoechst Ag Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof
DE4411025A1 (de) * 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
JP2879321B2 (ja) * 1996-03-14 1999-04-05 久保田 豊秋 動物用経口組成物
EP0862863B9 (en) * 1997-01-09 2009-08-12 Societe Des Produits Nestle S.A. Cereal product containing probiotics
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
FI110668B (fi) * 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
RU2246537C2 (ru) * 2002-11-11 2005-02-20 Закрытое акционерное общество "КУЛ" Штамм бактерий bacillus subtilis, используемый для получения пробиотического препарата, предназначенного для профилактики и лечения желудочно-кишечных заболеваний сельскохозяйственных животных, птицы и рыбы
US7247299B2 (en) * 2002-11-27 2007-07-24 Kemin Industries, Inc. Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens
JP4189224B2 (ja) * 2003-01-14 2008-12-03 株式会社カンサイ バチルス属に属する微生物及びそれを用いる防除剤
KR100535912B1 (ko) * 2003-12-17 2005-12-09 주식회사 케이티앤지 신규한 미생물 바실러스 아밀로리쿼페이션스 케이티지비0202 및 이를 이용한 식물병원균의 방제방법
JP2005198518A (ja) * 2004-01-13 2005-07-28 Asahi Business Support Co Ltd 海苔屑分解処理法及び微生物
RU2270858C2 (ru) * 2004-03-30 2006-02-27 Институт биологии Уфимского научного центра РАН Штамм бактерий b. subtilis - продуцент сурфактина
US7854927B2 (en) * 2004-05-11 2010-12-21 Ganeden Biotech, Inc. Methods and compositions for the dietary management of autoimmune disorders

Also Published As

Publication number Publication date
JP2013173750A (ja) 2013-09-05
US20080057047A1 (en) 2008-03-06
EP1956914B1 (en) 2014-01-08
CN101448398A (zh) 2009-06-03
RU2008121602A (ru) 2009-12-10
CN101448398B (zh) 2013-05-08
CA2631289A1 (en) 2007-06-07
BRPI0619364A2 (pt) 2011-09-27
JP5280854B2 (ja) 2013-09-04
NZ569244A (en) 2012-07-27
ZA200804646B (en) 2011-11-30
WO2007064741A3 (en) 2008-05-08
AU2006320613B2 (en) 2012-08-16
EP1956914A4 (en) 2011-12-21
RU2412241C2 (ru) 2011-02-20
WO2007064741A2 (en) 2007-06-07
EP1956914A2 (en) 2008-08-20
IL191795A0 (en) 2009-02-11
JP2009519238A (ja) 2009-05-14
WO2007064741A8 (en) 2008-01-31
KR20080073771A (ko) 2008-08-11
CA2631289C (en) 2015-01-06
KR101470352B1 (ko) 2014-12-09
AU2006320613A1 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
IL191795A (en) Use of Bacillus 6pb for the preparation of drugs for the prevention or treatment of gastrointestinal and related disorders @ the @ immune system
Lebeer et al. Identification of probiotic effector molecules: present state and future perspectives
JP2009519238A5 (enExample)
GB2460781A (en) Probiotic bifidobacterium strains
MY146590A (en) Probiotic bifidobacterium strains
GB2480773A (en) Compositions and methods for the treatment or the preventation oral infections by E.Coli
Bolla et al. Protective effect of a mixture of kefir-isolated lactic acid bacteria and yeasts in a hamster model of Clostridium difficile infection
NZ603065A (en) Method for using a bacillus subtilis strain for prophylaxis and treatment of gastro-intestinal conditions
WO2008077614A3 (de) Verwendung einer zusammensetzung aus mineralstoffen und gegebenenfalls acetogenen und/oder butyrogenen bakterien zur vermeidung oder reduzierung von gasbildung im dickdarm eines säugetiers und dadurch bedingter abdominaler beschwerden
UA100551C2 (en) Synbiotic mixture
AU2006253006A8 (en) Feline probiotic Lactobacilli
MX2022003374A (es) Cepas bacterianas, sus composiciones y su uso para el tratamiento de trastornos gastrointestinales.
MX2022000369A (es) Cepa bacteriana de bifidobacterium bifidum, las composiciones de la misma y usos relacionados.
SE0402406D0 (sv) Probiotic lactobacillus strains for improved vaginal health
MX2009012255A (es) Probioticos en ambiente pre y/o postquirurgico.
WO2007136719A3 (en) Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof
MX2012005524A (es) Cepa de probioticos bifidobacterium.
PH12013501408A1 (en) A nutritional composition comprising fiber and probiotics for reducing stress-related intestinal symptoms
NZ594019A (en) Novel antibacterial agents for the treatment of gram positive infections
RU2014107771A (ru) ШТАММЫ МОЛОЧНО-КИСЛЫХ БАКТЕРИЙ И/ИЛИ БИФИДОБАКТЕРИЙ, ИНГИБИРУЮЩИЕ/УМЕНЬШАЮЩИЕ РОСТ РАЗЛИЧНЫХ БИОТИПОВ E.coli И РАЗЛИЧНЫХ БИОТИПОВ КЛОСТРИДИЙ
JP2013147469A5 (enExample)
JP2013522315A5 (enExample)
DK1624762T3 (da) Probiotisk præparat med mindst to mælkesyrebakteriestammer som er i stand til kolonisere mavetarmkanalen, i kombination med at de besidder overlevelsesegenskab, tarmbindende egenskab, en infektionsbeskyttelsesegenskab og en fiberfermenterende egenskab
MXPA04005002A (es) Bacterias lacticas y su uso en el tratamiento y la prevencion del cancer.
Nuñez et al. Caracterización genética de bacterias endofíticas de arroz (Oryza sativa L.) con actividad antimicrobiana contra Burkholderia glumae

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees